Is co-option a prevailing mechanism during cancer progression?

Cancer Research

Volumn 71, Issue 21, 2011, Pages 6572-6575

  Billaud, Marc ^a   Santoro, Massimo ^b  

^a INSTITUT ALBERT BONNIOT   (France)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; LYSOPHOSPHATIDIC ACID; ONCOPROTEIN; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN;

AEROBIC METABOLISM; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CELL METABOLISM; CO OPTION PHENOMENON; COX2 GENE; EPITHELIAL MESENCHYMAL TRANSITION; EVOLUTION; GAIN OF FUNCTION MUTATION; GENE; GLYCOLYSIS; HOMEOSTASIS; HUMAN; METASTASIS; ONCOGENE; ONCOGENE MET; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STRUCTURAL GENE; THEORY; THROMBOCYTE FUNCTION; WARBURG EFFECT;

ADAPTATION, BIOLOGICAL; ANIMALS; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; EVOLUTION, MOLECULAR; GENE DUPLICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HEMOSTASIS; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SELECTION, GENETIC; SUBSTRATE SPECIFICITY;

EID: 80155205774     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2158     Document Type: Review

References (36)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
2. Hanahan D Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
3. Stratton MR Campbell PJ Futreal PA. The cancer genome. Nature 2009;458:719-24.
4. Kinzler KW Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70. (Pubitemid 26358996)
5. Fidler IJ Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197:893-5. (Pubitemid 8168759)
6. Bernards R Weinberg RA. A progression puzzle. Nature 2002;418:823.
7. Jacob F. Evolution and tinkering. Science 1977;196:1161-6.
8. True JR, Carroll SB. Gene co-option in physiological and morphological evolution. Annu Rev Cell Dev Biol 2002;18:53-80. (Pubitemid 35387345)
9. Gould SJ Lewontin RC. The spandrels of San Marco and the Panglossian paradigm: a critique of the adaptationist programme. Proc R Soc Lond B Biol Sci 1979;205:581-98. (Pubitemid 10248042)
10. Songyang Z Carraway KL Eck MJ Harrison SC Feldman RA Mohammadi M, et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 1995;373:536-9.
11. Griswold IJ MacPartlin M Bumm T Goss VL O'Hare T Lee KA, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006;26:6082-93.
12. Choudhary C Olsen JV Brandts C Cox J Reddy PN Bohmer FD, et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009;36:326-39.
13. Dang L White DWGross S Bennett BD Bittinger MA Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010;465:966.
14. Christofk HR Vander Heiden MG Harris MH Ramanathan A Gerszten RE Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230-3.
15. Thiery JP Acloque H Huang RY Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
16. Mani SA Guo W Liao MJ Eaton EN Ayyanan A Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
17. Ansieau S Bastid J Doreau A Morel AP Bouchet BP Thomas C, et al. Induction of EMT by twist proteins as a collateral effect of tumorpromoting inactivation of premature senescence. Cancer Cell 2008;14:79-89.
18. Vander Heiden MG Cantley LC Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
19. Kroemer G Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-82. (Pubitemid 351766797)
20. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol 2001;69:522-30. (Pubitemid 32294836)
21. Swietach P Vaughan-Jones RD Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007;26: 299-310. (Pubitemid 47101667)
22. Yang MH Wu MZ Chiou SH Chen PM Chang SY Liu CJ, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008;10:295-305.
23. Esteban MA Tran MG Harten SK Hill P Castellanos MC Chandra A, et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006;66:3567-75.
24. Luo W Hu H Chang R Zhong J Knabel M O'Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011;145:732-44.
25. Gupta GP Nguyen DX Chiang AC Bos PD Kim JY Nadal C, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765-70.
26. Holash J Maisonpierre PC Compton D Boland P Alexander CR Zagzag D, et al. Vessel co-option, r-egression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284, 1994-8.
27. Boccaccio C Comoglio PM. A functional rôle for hemostasis in early cancer development. Cancer Res 2005;65:8579-82. (Pubitemid 41377338)
28. Boccaccio C Sabatino G Medico E Girolami F Follenzi A Reato G, et al. The MET oncogène drives a genetic programme linking cancer to hemostasis. Nature 2005;434:396-400.
29. Nash GF Turner LF Scully MF Kakkar AK. Platelets and cancer. Lancet Oncol 2002;3:425-30. (Pubitemid 36958273)
30. Boucharaba A Serre CM GrËs S Saulnier-Blache JS Bordet JC Guglielmi J, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004;114:1714-25.
31. Gupta GPMassagué J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest 2004;114:1691-3.
32. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-4. (Pubitemid 34743088)
33. Sharma SV Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007;21:3214-31. (Pubitemid 350277749)
34. Maley CC Galipeau PC Finley JC Wongsurawat VJ Li X Sanchez CA, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38:468-73.
35. Stephens PJ Greenman CD Fu B Yang F Bignell GR Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27-40.
36. Navin N Kendall J Troge J Andrews P Rodgers L McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472:90-4.